W e sincerely apologize for the inappropriate and unacceptable intellectual overlap and selfplagiarism of our paper cited above with a paper published in Anesthesiology. 1 Both studies sought to determine the impact of different forms of postoperative noninvasive ventilation versus standard of care in bariatric surgical patients, and thus dealt with identical challenges and knowledge base, and very similar populations. In presenting the results of the two studies, we duplicated much of the Introduction, structure of the Methods and Results, and the Discussion sections. Despite the data being original in each paper, this is a clear violation of the policies of both Anesthesia & Analgesia (A&A) and Anesthesiology.
We also fully understand that the difference between the methods of delivery of postoperative airway support in the two papers (Boussignac mask for continuous positive airway pressure [CPAP] vs. Esprit portable ventilator for inspiratory positive airway pressure support and CPAP) would have potentially been found by the editors to be insufficient to justify independent papers. Unfortunately, because of the delays and overlap of our attempts to publish both sets of information, we neglected to reference the paper in Anesthesiology in the final revision of the A&A paper. Had this citation appeared, we now realize that the incremental nature would have likely resulted in its rejection from A&A.
Consequently, we the faculty authors request that our paper be retracted because of self-plagiarism and incremental new knowledge. We hope that our mistake does not detract from future research into the potential benefits of immediate postoperative ventilatory support. Walk a Mile in Whose Shoes?
To the Editor F isher and Shafer raise 3 issues in an editorial 1 accompanying our article 2 on the problem of practice misalignments in clinical trials. First, the editorial implies that misalignments commonly occur in clinical research and are mandated by regulatory agencies. To support this view, the editorialists offer 4 trial types as examples: "pharmaceutical industry trials," "trials where placebos are acceptable," "bioequivalence trials," and "clinical pharmacology dosing studies." Second, they argue that time constraints and monetary costs prevent clinical investigators from addressing the misalignment problem. Finally, they conclude that despite lengthy deliberations and due diligence, misalignments may be unavoidable.
Trials adversely affected by practice misalignments investigate routinely used interventions that are titrated based on clinical factors to maximize benefit or limit risk. 3 Such trials are of little interest to the pharmaceutical industry. Importantly, the Food and Drug Administration does not require trial designs confounded by such practice misalignments. Moreover, practice misalignments jeopardizing patient safety are unlikely in trials for which placebos are an acceptable alternative to usual care. Bioequivalence studies typically compare an established drug against a new one. Dose is not titrated and 1 group of patients will receive a previously approved drug. Pharmacology studies are usually small phase I or phase II new drug investigations exploring the relationship between dose and treatment effects. Although patients can be harmed in these studies, drug dose is not knowingly misaligned with patient need through randomization.
As previously defined, serious practice misalignments occur in trials of established interventions routinely titrated at the bedside for life-threatening conditions. 4,5 Large phase III trials facilitate identification of the misaligned subgroups. Affected studies have no placebo group and neither arm adequately represents practice outside of the trial. 4, 5 Randomization changes patients from individualized care to fixed, widely differing levels of treatment, independent of perceived need or an assessment of risks and benefits. Harmful misalignments may thereby be created if clinical practice outside of the trial has any validity. The absence of an appropriate control group precludes effective safety monitoring, particularly in trials with high background morbidity and mortality.
One of several possible approaches, discussed in our article, to improve safety and validity of the trials cited above would have been the addition of a third arm-a true control group representing routine practice. Fisher and Shafer do not directly disagree with the safety advantages or scientific merit of alternative trial designs. Rather, they argue that adding a third arm would increase the amount of time needed to complete trials and cost too much money. However, as discussed in our article, addressing the problem of practice misalignments does not invariably require the addition of a third arm.
Lastly, the editorial opines that lengthy deliberations may not prevent misalignments. Although correct, the quality and safety of clinical trials will benefit by making trialists, funding agencies, and institutional review boards more aware of this potential pitfall. Fisher and Shafer conclude that "the most efficient design to answer the question may be a fixed dose clinical trial, despite practice misalignment" and ask us to walk a mile in the shoes of clinical investigators. Efficiency does not trump patient safety. Before consciously undertaking a trial with serious practice misalignments, we should walk a mile in the shoes of a critically ill research subject.
In Response
Deans et al. 1 argue that "efficiency should not trump patient safety." Who could argue with that? But, rarely is the answer as clearcut as Deans et al. imply. In many clinical situations, clinicians and investigators have strong opinions as to what therapy is best, yet a multitude of such opinions exist. 2 Deans' colleagues at the National Institutes of Health (NIH) challenged the appropriateness of the ARDSNet study (a well-regarded study comparing 2 modes of mechanical ventilation in critically ill adults), leading the NIH to suspend the trial pending external review. 2 Expert panels concluded that the trial design was appropriate and the trial resumed with NIH support. 3 Deans et al. may be unhappy with the conduct and results of that trial. If so, I encourage them to conduct a new trial that contains what they contend to be appropriate treatments. If their arguments are sound, it should not be difficult to obtain funding and recruit investigators. An IRB will presumably apply the same rigor to their protocol as was applied to each of the "misaligned" trials that they cite, thereby assuring that the interests of patients are protected.
Despite these authors' suggestion to the contrary, efficiency must be considered in a clinical trial, although not at the expense of patient safety. If the trial design prevents its completion, investigators have committed the most egregious breach of ethics: exposing patients to the risk of the trial (every treatment arm, even what Deans et al. would deem "usual care," has risks) without any benefit to the participants or to society. Thompson and Schoenfeld, 4 commenting on the ARDSNet trial, arrived at a similar conclusion: "addition of a usual-care arm to a two-arm trial will, under most circumstances, result in additional harm to research subjects, substantially increase the cost and complexity of clinical trials, and delay the acquisition of knowledge."
Nobody should walk in shoes that lead nowhere.
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